Skip to Main Content

  • Image not available. Lung cancer is the leading cause of cancer deaths in both men and women in the United States. The overall 5-year survival rate for all types of lung cancer is approximately 15%.
  • Image not available. Cigarette smoking is responsible for most lung cancers. Smoking cessation should be encouraged, particularly in those receiving curative treatment (i.e., stages I to IIIA non–small cell lung cancer and limited-stage small cell lung cancer).
  • Image not available. Non–small cell lung cancer (NSCLC) is diagnosed in most (˜80%) lung cancer patients. NSCLC typically has a slower growth rate and doubling time than small cell lung cancer (SCLC).
  • Image not available. No screening test is currently recommended to identify lung cancer. However, several studies are evaluating different methods of screening in an attempt to diagnose lung cancer at an earlier stage, when it should be more curable.
  • Image not available. Treatment decisions are guided by the stage of disease, which is characterized by tumor size and spread. Patient-specific factors (i.e., performance status, co-morbid conditions, etc.) must also be considered when developing a treatment plan.
  • Image not available. The treatment goals in lung cancer are cure (early-stage disease), prolongation of survival, and maintenance or improvement of quality of life through alleviation of symptoms.
  • Image not available. Early-stage lung cancer has the highest cure rates when surgical resection of the tumor is used with or without chemotherapy for NSCLC and chemoradiotherapy for SCLC.
  • Image not available. Advanced-stage lung cancer is primarily treated with systemic therapy. Doublet chemotherapy regimens are superior in response to single-agent regimens and should be used when the patient can tolerate the associated toxicity. Platinum-containing doublets are first-line treatment in most cases of NSCLC and SCLC.
  • Image not available. Optimal patient care needs to include prevention and treatment of adverse events from chemotherapy. Adverse events may cause delays in chemotherapy administration, increase morbidity, and contribute to treatment failure.

On completion of the chapter, the reader will be able to:

  • 1. Explain the importance of lung cancer mortality relative to other cancers.
  • 2. Describe the relationship between cigarette smoking and lung cancer.
  • 3. Contrast the risk of lung cancer between former smokers and those who never smoked cigarettes.
  • 4. List the most prevalent cell types of carcinomas in the lung.
  • 5. Contrast the frequency of non–small cell lung cancer (NSCLC) and small-cell lung cancer (SCLC).
  • 6. Briefly describe why lung cancer screening is not currently recommended
  • 7. Contrast the role of surgery for stage I/II and stage IV NSCLC.
  • 8. Describe the role of radiotherapy for stage I/II NSCLC.
  • 9. List the potential treatment regimens for locally advanced NSCLC stage IIB, IIIA, and IIIB.
  • 10. List the prognostic factors for survival in stage IV NSCLC patients.
  • 11. Choose a chemotherapy regimen for the initial treatment of stage IV NSCLC in those with favorable prognostic factors.
  • 12. List the treatment options for NSCLC patients who progress after first-line chemotherapy.
  • 13. Explain which patient population is most likely to respond to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors.
  • 14. Describe ...

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.